







REPORTING	PHYSICIAN	
Report Date: JUL-27-2020	John Miller	
Receipt Date: JUL-18-2020		
Collection Date: JUL-17-2020	Account: Pleasantville Oncology	
Specimen: Blood	Address: 1234 Main Street	
Status: FINAL	Redwood City, CA 94063, United States	
	Ph: (123) 456-7890 Fax: (123) 456-7899	
	Additional Recipient: N/A	Complete Tumor Response Map on page 2

This content is provided as a professional service and has not been reviewed or approved by the FDA

Summary of Somatic Alterations & Associated Treatment Options

KEY  Approved in indication  Approved in other indication  Lack of response

Detected Alteration(s) / Biomarker(s)	Associated FDA-approved therapies	Clinical trial availability (see page 4)	% cfDNA or Amplification
MSI-High	 Pembrolizumab, Nivolumab	Yes	—
BRAF V600E	 Cetuximab, Encorafenib, Panitumumab  Binimetinib, Cobimetinib, Trametinib, Vemurafenib	Yes	19.8%
PIK3CA E545A	 Alpelisib, Copanlisib	Yes	4.2%
CDKN2A R58*	 Abemaciclib, Palbociclib, Ribociclib	Yes	4.0%

Variants of Uncertain Significance
KIT C443fs (Exon 8 insertion) (7.2%), APC H768R (6.7%), CDK12 L1033P (6.5%), NOTCH1 V2319A (5.3%)
The functional consequences and clinical significance of alterations are unknown. Relevance of therapies targeting these alterations is uncertain.

Additional Biomarkers

Biomarker	Additional Details
MSI-High	DETECTED

Alterations or biomarkers that were "NOT DETECTED" have been excluded from the summary table above.

We evaluated this sample for 74 genes, including the following guideline-recommended genes for CRC

MSI-High

KRAS

NRAS

BRAF

ERBB2(HER2)

NTRK

This content is provided as a professional service and has not been reviewed or approved by the FDA